{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["Colorectal Neoplasms","Advanced Colorectal Cancer"],"disease":["Colorectal Neoplasms","Advanced Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2219329"],"study_start_month":["9"],"keyword":["Cetuximab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"LEAC-102 for Advanced Colorectal Cancer","description":"A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer","dates":{"creation":"2022-09-15"},"accession":"2219329","cross_references":{"ClinicalTrials___gov":["NCT02826837"]}}